Avacta’s AVA6207 Overcomes Cancer Drug Resistance in Preclinical Studies
Bitget2026/11/19 07:13- Avacta presented preclinical results today in Barcelona showing AVA6207 reversed resistance to topoisomerase I inhibitors in laboratory studies and animal models.
- The dual-payload drug achieved complete responses in resistant ovarian and lung tumor models, supporting clinical development in biomarker-defined patient groups.
- AVA6207 also outperformed Enhertu in a gastric tumor model.
- Payloads have been selected, with the clinical candidate moving into studies supporting an investigational new drug application in the fourth quarter of 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

